PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher Holdings (OTCQB:PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former's novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.
PharmAther Holdings（OTCQB: PHRRF）和 寺崎生物醫學創新研究所 評估了前者用於輸送DMT的新型微針貼劑，研究得出了積極的結果。
The study sought to develop a suitable prototype of PharmaPatch for DMT's transdermal delivery to overcome obstacles associated with oral and IV administration routes.
該研究旨在爲DMT的透皮給藥開發合適的PharmaPatch原型，以克服與口服和靜脈給藥途徑相關的障礙。
Research provided a full characterization of DMT conjugated on the microneedle patch backbone, establishment and demonstration of the loading capacity for DMT, and release rate evaluations for the psychedelic-conjugated materials.
研究提供了在微針貼片主幹上偶聯的DMT的完整表徵，建立和演示了DMT的負荷能力，並對迷幻共軛材料的釋放率進行了評估。
DMT microneedles have reportedly been "successfully fabricated, optimized, and characterized," and demonstrated "acceptable performance" in male and female rats.
據報道，DMT 微針已經 “成功製作、優化和表徵”，並在雄性和雌性大鼠身上表現出 “可接受的性能”。
The authors state that the smooth incorporation of DMT into microneedles along with the demonstrated complete ex-vivo skin model release over several days hints at the potential for larger doses, modified controlled-release profiles, and microdosing.
作者指出，將DMT順利融入微針中，以及在幾天內展示的完整體外皮膚模型發佈，這表明有可能增加劑量、修改控釋特徵和微劑量。
Entering The Clinic
進入診所
PharmaPatch's delivery technology is reportedly based on novel biocompatible and biodegradable gelatin methacryloyl (GelMA) material to deliver water-soluble and insoluble drugs with specified release profiles in a safe and efficient manner by penetrating the outer layer of the skin.
據報道，PharmaPatch的遞送技術基於新型的生物相容性和可生物降解的明膠甲基丙烯酰基（GelMA）材料，通過穿透皮膚的外層，以安全高效的方式輸送具有特定釋放特徵的水溶性和不溶性藥物。
PharmaTher completed research studies demonstrating that its microneedle patch can deliver other psychedelics including psilocybin, MDMA and LSD, and believes PharmaPatch's achieved prototype is acceptable for completing IND-enabling studies toward entering clinical studies next.
PharmaTher完成的研究表明，其微針貼劑可以提供其他迷幻藥，包括psilocybin、MDMA和LSD，並認爲PharmaPatch實現的原型對於完成支持IND的研究以進入臨床研究是可以接受的。
The company will work with its research partner PharmaDrug Inc., as well as invest $227,700 (CA$300,000) in the latter's subsidiary, Sairiyo Therapeutics, for a 49% ownership.
該公司將與其研究合作伙伴PharmaDrug Inc. 合作，並向後者的子公司Sairiyo Therapeutics投資227,700美元（合30萬加元），持有49％的所有權。
Sairiyo is developing novel uses and delivery forms of DMT and other undisclosed tryptamines as a potential treatment for ocular disease and neuropsychiatric conditions.
Sairiyo正在開發DMT和其他未公開的色胺的新用途和遞送形式，作爲眼部疾病和神經精神疾病的潛在治療方法。
In connection with the investment, PharmaDrug and PharmaTher will enter into a unanimous shareholders agreement regarding their Sairiyo holdings, concerning management appointment rights and the constitution of the board of directors and shareholders' entitlement to subscribe for new share issuances on a pro-rata basis.
在投資方面，PharmaDrug和PharmaTher將就其持有的Sairiyo股份達成一致的股東協議，內容涉及管理層任命權以及董事會組成和股東按比例認購新股發行的權利。
Wondering about the latest in the cannabis business world? Get ahead by attending Benzinga's Cannabis Capital Conference!
想知道大麻商業界的最新消息嗎？參加 Benzinga 的大麻資本會議，取得成功！
Taking place in Chicago on Sept 27-28, the 17th edition of CCC is the place to get DEALS DONE. Join us by getting your tickets today before prices increase.
第17屆CCC將於9月27日至28日在芝加哥舉行，是完成交易的地方。在價格上漲之前立即獲取門票，加入我們。
Photo: Benzinga edit with photo by DyrElena by Shutterstock and Wikimedia Commons.
照片：Benzinga 使用由 Shutterstock 和 Wikimedia Commons 拍攝的 dyreLena 照片進行編輯。